Health Care/Hospital

MingMed to Present at the 40th Annual J.P. Morgan Healthcare Conference

GUANGZHOU, China, Jan. 6, 2022 /PRNewswire/ -- MingMed Biotechnology, a clinical stage company dedicated to developing First-in-Class pharmaceutical products, today announced that Ms.Liza Ko, Chief Financial Officer of the company, has been invited to present at the 40th Annual J.P. Morgan Health...

2022-01-06 09:00 2660

CSafe Global Launches Real-Time Shipment Visibility for Passive Portfolios

CSafe now offers real-time visibility and online ordering for VIP Parcel and Cell & Gene Solutions.    DAYTON, Ohio, Jan. 6, 2022 /PRNewswire/ -- CSafe Global, the innovation leader in temperature-controlled solutions for the pharmaceutical industry, announced today it has expanded its real-time...

2022-01-06 00:01 2691

Tools4Patient Announces Name Change to Cognivia & Expands Board of Directors

MONT-SAINT-GUIBERT, Belgium, Jan. 5, 2022 /PRNewswire/ -- Cognivia today announced a new name for the company formerly known as Tools4Patient, which provides clinical trials solutions based on AI / ML that account for individual patient personality traits, beliefs and perceptions. The transition ...

2022-01-05 23:00 2098

IMG Launches PTOgo, a New Travel Medical Product for Employers and Employees Traveling Abroad

INDIANAPOLIS, Jan. 5, 2022 /PRNewswire/ -- International Medical Group® (IMG®) is excited to introduce PTOgo, a first-of-its-kind travel medical insurance offering for employers and employees that provides accident and sickness coverage for international trips during paid time off. Offered as an ...

2022-01-05 22:00 1910

Insilico Medicine Announces the Nomination of Two Preclinical Candidates for PHD2, 12 Months After Program Initiation

NEW YORK and SHANGHAI, Jan. 5, 2022 /PRNewswire/ -- Insilico Medicine, a global clinical-stage biotechnology company specializing in the applications of end-to-end artificial intelligence (AI) for drug discovery and development, today announced that the company has nominated preclinical candidate...

2022-01-05 17:00 1978

Antengene to Present at the 40th Annual J.P. Morgan Healthcare Conference

SHANGHAI and HONG KONG, Jan. 5, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncol...

2022-01-05 12:50 2624

Introducing Multilayer Clear Aligner Material: TRISTAR by Whitesmile Clear.

KUALA LUMPUR, Malaysia, Jan. 5, 2022 /PRNewswire/ -- Whitesmile Clear, Southeast Asia's largest clear aligner manufacturing company of Visivest Corporation (M) Sdn Bhd, today announced the start of commercial sales of Tristar, a unique composite material engineered specifically for the fabricati...

2022-01-05 12:00 3081

IND Approved for Pivotal Clinical Study of HER2 Bispecific Antibody KN026 Combined with Chemotherapy in Gastric Cancer

SUZHOU, China, Jan. 5, 2022 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. (stock code: 1093.HK) jointly announced that the IND application for the pivotal clinical trial (KN026-CSP-001) of the anti-HER2 bispecific antibody KN026 combined with che...

2022-01-05 11:49 4206

COVID-19 Oral Vaccine and Antibody Booster: B. subtilis Spores, Biotechnology Breakthrough by DreamTec

HONG KONG, Jan. 5, 2022 /PRNewswire/ -- Vaccines have been a trending topic ever since the coronavirus outbreak two years ago. DreamTec Research Limited (DreamTec,http://www.dreamtec.hk ) has its major breakthrough in developing a COVID-19 oral vaccine. In its recently pu...

2022-01-05 10:00 2837

SI GROUP APPOINTS RUSTOM JILLA AS NEW CHIEF FINANCIAL OFFICER

Jilla brings nearly 20 years of international CFO experience including transformational change SCHENECTADY, N.Y., Jan. 5, 2022 /PRNewswire/ -- SI Group, a leading performance additives company, announced today the appointment ofRustom Jilla as its Senior Vice President and Chief Financial Office...

2022-01-05 02:00 2437

CAI Announces CEO Succession

INDIANAPOLIS, Jan. 4, 2022 /PRNewswire/ -- CAI, a global consulting company that provides technical, operational consulting, and project management services to life sciences, data centers, and industrial process manufacturing industries, today announcedMichael Martin, CAI President, will succeed ...

2022-01-04 22:33 2296

Molecular Stethoscope, Inc. establishes new Corporate Headquarters and Research & Development Laboratories in South San Francisco and appoints Gajus Worthington to its Board of Directors

SOUTH SAN FRANCISCO, Calif., Jan. 4, 2022 /PRNewswire/ -- Molecular Stethoscope, a leading Precision Medicine biotechnology company pioneering the next-generation cf-mRNA Liquid Biopsy, announced today that it has joined Verily Life Sciences ("Verily") partnered laboratory ecosystem inSouth San ...

2022-01-04 19:00 1339

Alamar Biosciences partners with Abcam to drive understanding of the human proteome

FREMONT, Calif. and CAMBRIDGE, England, Jan. 4, 2022 /PRNewswire/ -- Alamar Biosciences  (Alamar), a platform company focused on transforming the field of proteomics to enable the early detection of cancer and other diseases, and Abcam (AIM: ABC...

2022-01-04 17:00 1805

Affiliates Flock to Seal Partnerships with Malaysia Healthcare at Expo 2020 Dubai

DUBAI, UAE, Jan. 4, 2022 /PRNewswire/ -- Malaysia's healthcare travel industry led by the Malaysia Healthcare Travel Council (MHTC), welcomed more new partnerships at the Malaysia Pavilion in Expo 2020 Dubai. Memorandums of Understanding (MoUs) were exchanged with renowned players such as Interna...

2022-01-04 15:32 1418

Breakthrough Discoveries on Novel Features of Omicron Variant and An Anti-Omicron Antibody JMB2002

SHANGHAI, Jan. 4, 2022 /PRNewswire/ -- Joint research results from Biologics of Jemincare and Shanghai Institute ofMateria Medica (SIMM) of Chinese Academy of Sciences (CAS) confirmed that JMB2002, an anti-SARS-CoV-2 neutralizing antibody (NAb) discovered by Biologics of Jemincare is still effect...

2022-01-04 10:00 2930

Gannex Announces Completion of the U.S. Phase I Trial of ASC43F, an In-House Developed First-in-Class Dual Targeting Fixed-dose Combination Tablet for NASH

* ASC43F was safe and well tolerated in healthy subjects with no clinically significant study drug related adverse events * Pharmacokinetic parameters of ASC41 and ASC42 from ASC43F are similar to those of ASC41 and ASC42 monotherapy * Phase I trial completed two months after the U.S. IND ap...

2022-01-04 08:30 2794

Everest Medicines Announces Taiwan FDA Has Accepted New Drug Application for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer

SHANGHAI, Jan. 4, 2022 /PRNewswire/ -- Everest Medicines Limited (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products inAsia, announced today that T...

2022-01-04 08:00 2908

Sihuan Pharmaceutical (0460.HK): Sunshine Life Insurance Leads Investment in Xuanzhu Biopharm

HONG KONG, Jan. 3, 2022 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd. (the "Company" or "Sihuan Pharmaceutical", together with its subsidiaries, collectively referred to as the "Group"; Hong Kong Stock Exchange stock code: 0460) is pleased to announce that, its subsidiary Xuanzhu...

2022-01-03 14:24 6421

Ascletis Expands Ritonavir Oral Tablet Production and Announces Oral Direct-Acting Antiviral Pipeline Against SARS-CoV-2 Virus

- Ritonavir oral tablet annual production capacity has been expanded to 100 million tablets and can be further rapidly expanded based on market demand - ASC10 is an oral direct-acting antiviral drug candidate targeting RNA dependent RNA polymerase (RdRp) to treat SARS-CoV-2 infection - ASC11 is ...

2022-01-03 08:30 3295

CStone Pharmaceuticals announced the IND approval of CS5001, a potential global best-in-class ROR1-targeting ADC by the U.S. Food and Drug Administration

SUZHOU, China, Jan. 3, 2022 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on the research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today announced that the investigational new ...

2022-01-03 08:00 3523
1 ... 234235236237238239240 ... 551

Week's Top Stories